Scotia Capital’s MiMedx Group MDXG Stock Holding History

Scotia Capital’s Portfolio MDXG Stock Details MDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,706	Closed	-$155K	–	858
2023 Q4	$155K	Sell	17,706 -133	-0.7%	-$974	﹤0.01%	752
2023 Q3	$130K	Buy	+17,839	New	+$133K	﹤0.01%	729

Other funds holding MDXG

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Scotia Capital's MDXG Position: Q1 2024 in Review

Scotia Capital sold out of MiMedx Group (MDXG) in Q1 2024, closing a stake of 17,706 shares — an estimated $155K sold.

Scotia Capital first reported a position in MDXG in Q3 2023 and held it in 2 quarters. The position peaked at $155K in Q4 2023. 202 funds tracked by Wall St. Rank hold MDXG as of Q1 2024.

Scotia Capital reported no remaining MiMedx Group position as of Q1 2024 after selling out during the quarter.
Scotia Capital sold 17,706 MiMedx Group shares in Q1 2024, an estimated $155K.
Scotia Capital first reported a position in MiMedx Group in Q3 2023 and held it in 2 quarters.
Scotia Capital's MiMedx Group position peaked at $155K in Q4 2023.
202 funds tracked by Wall St. Rank held MiMedx Group as of Q1 2024.

Based on Scotia Capital's 13F filing for Q1 2024, filed 14 May 2024.